ASSESSMENT OF INDUCED SPUTUM TO EVAL ANTI-INFLAMMATORY AGENTS IN PTS W/CF

诱导痰评估以评估 PTS W/CF 中的抗炎药物

• 批准号: 7374377
• 负责人: JEFFREY S WAGENER
• 金额: $ 1.62万
• 依托单位: UNIVERSITY OF COLORADO DENVER
• 依托单位国家: 美国
• 财政年份: 2006
• 资助国家: 美国
• 起止时间: 2006-04-24 至 2007-02-28
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7374377
• 关键词: arm; clinical trials; corticosteroids; cystic fibrosis; ibuprofen; lung; sputum

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Inflammatory contributes to the progression of cystic fibrosis (CF) lung disease. Anti-inflammatory therapy of corticosteroids in patients with CF have shown clinical benefit, but adverse effects have limited their use. Results from the clinical trials of alternate-day corticosteriods and high-dose ibuprofen in CF indicate anti-inflammatory therapy will slow the rate of decline. This study is a two arm, multicenter, randomized, open-label, controlled, parallel-group trial comparing the effects of 28 days of ibuprofen, or no treatment on inflammatory mediators in induced sputum in subjects with mild to moderate CF lung disease.

该子项目是利用 NIH/NCRR 资助的中心拨款提供的资源的众多研究子项目之一。子项目和研究者 (PI) 可能已从另一个 NIH 来源获得主要资金，因此可以在其他 CRISP 条目中出现。列出的机构是中心的机构，不一定是研究者的机构。炎症会导致囊性纤维化（CF）肺病的进展。 CF 患者的皮质类固醇抗炎治疗已显示出临床益处，但不良反应限制了其使用。隔日皮质类固醇和大剂量布洛芬治疗 CF 的临床试验结果表明，抗炎治疗将减缓病情恶化的速度。本研究是一项双臂、多中心、随机、开放标签、对照、平行组试验，比较布洛芬 28 天或不治疗对轻度至中度 CF 肺病受试者诱导痰中炎症介质的影响。